Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI3002 in asthma
NCT07015749Phase 1Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jun 2025
- Primary completion
- May 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IBI3002 in asthma (6 arms), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Safety and Tolerability. Started Jun 2025; status: recruiting.
02
Drugs
IBI3002
03
Conditions
asthma
Beyond the preview
Go deeper on NCT07015749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07015749.